Analyst Ratings for [GSK] GlaxoSmithKline PLC

6/3/25	Downgrades	Buy Hold	X
GSK GlaxoSmithKline Berenberg
4/15/25	Initiated	Neutral	X
GSK GlaxoSmithKline Exane BNP Paribas
$35.25
2/12/25	Initiated	Equal-Weight	X
GSK GlaxoSmithKline Morgan Stanley
11/15/24	Downgrades	Buy Hold	X
GSK GlaxoSmithKline Deutsche Bank
11/12/24	Downgrades	Buy Hold	X
GSK GlaxoSmithKline Jefferies
$53 $39.50
10/31/24	Downgrades	Buy Neutral	X
GSK GlaxoSmithKline Guggenheim
7/8/24	Downgrades	Buy Neutral	X
GSK GlaxoSmithKline UBS
5/30/24	Initiated	Neutral	X
GSK GlaxoSmithKline Goldman
$47
3/4/24	Upgrades	Neutral Buy	X
GSK GlaxoSmithKline Guggenheim
2/13/24	Upgrades	Neutral Buy	X
GSK GlaxoSmithKline Citigroup
1/23/24	Initiated	Equal-Weight	X
GSK GlaxoSmithKline Morgan Stanley
$44
1/16/24	Resumed	Buy	X
GSK GlaxoSmithKline UBS
1/3/24	Upgrades	Hold Buy	X
GSK GlaxoSmithKline Jefferies
$48
7/14/23	Initiated	Reduce	X
GSK GlaxoSmithKline HSBC Securities
3/17/23	Upgrades	Hold Buy	X
GSK GlaxoSmithKline Deutsche Bank
2/27/23	Resumed	Buy	X
GSK GlaxoSmithKline Goldman
1/3/23	Downgrades	Neutral Underweight	X
GSK GlaxoSmithKline JP Morgan
12/5/22	Downgrades	Neutral Underperform	X
GSK GlaxoSmithKline BofA Securities
11/11/22	Downgrades	Neutral Sell	X
GSK GlaxoSmithKline UBS
9/15/22	Upgrades	Underperform Neutral	X
GSK GlaxoSmithKline Credit Suisse
9/8/22	Downgrades	Buy Hold	X
GSK GlaxoSmithKline Jefferies
$50.50 $34
8/5/22	Resumed	Equal-Weight	X
GSK GlaxoSmithKline Morgan Stanley
2/11/22	Downgrades	Buy Hold	X
GSK GlaxoSmithKline DZ Bank
11/5/21	Upgrades	Underweight Eq Weight	X
GSK GlaxoSmithKline Barclays
6/24/21	Upgrades	Sell Hold	X
GSK GlaxoSmithKline Deutsche Bank
3/23/21	Downgrades	Outperform Mkt Perform	X
GSK GlaxoSmithKline SVB Leerink
2/4/21	Downgrades	Hold Sell	X
GSK GlaxoSmithKline Deutsche Bank
1/20/21	Downgrades	Neutral Underperform	X
GSK GlaxoSmithKline Credit Suisse
1/15/21	Initiated	Hold	X
GSK GlaxoSmithKline Deutsche Bank
8/13/19	Resumed	Neutral	X
GSK GlaxoSmithKline JP Morgan
6/17/19	Resumed	Underweight	X
GSK GlaxoSmithKline Morgan Stanley
3/8/19	Downgrades	Buy Hold	X
GSK GlaxoSmithKline Shore Capital
2/22/19	Downgrades	Buy Neutral	X
GSK GlaxoSmithKline UBS
1/14/19	Downgrades	Outperform Neutral	X
GSK GlaxoSmithKline Exane BNP Paribas
12/11/18	Resumed	Buy	X
GSK GlaxoSmithKline Jefferies
10/9/18	Initiated	Neutral	X
GSK GlaxoSmithKline Guggenheim
8/30/18	Downgrades	Buy Hold	X
GSK GlaxoSmithKline Liberum
4/4/18	Upgrades	Neutral Outperform	X
GSK GlaxoSmithKline Exane BNP Paribas
3/22/18	Upgrades	Underweight Eq-Weight	X
GSK GlaxoSmithKline Morgan Stanley
2/9/18	Upgrades	Reduce Hold	X
GSK GlaxoSmithKline Kepler

GSK GlaxoSmithKline PLC

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.